A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859 Meeting Abstract
| Authors: | Qin, S.; Tabernero, J.; van Cutsem, E.; Fuchs, C. S.; Janjigian, Y. Y.; Bhagia, P.; Li, K.; Adelberg, D.; Bang, Y. J. |
| Abstract Title: | A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859 |
| Meeting Title: | ESMO Asia Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2020 Nov 20-22 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-11-01 |
| Start Page: | S1316 |
| End Page: | S1317 |
| Language: | English |
| ACCESSION: | WOS:000600988900199 |
| DOI: | 10.1016/j.annonc.2020.10.461 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 197TiP -- Source: Wos |
